Diagnosis and Monitoring of Colorectal Cancer by L6 Blood Serum Polymerase Chain Reaction Is Superior to Carcinoembryonic Antigen-Enzyme-Linked Immunosorbent Assay

Schiedeck, Thomas; Wellm, Carsten; Roblick, Uwe J.; Broll, R.; Bruch, Hans–Peter

doi:10.1007/s10350-004-6662-6

Cited by 26 publications

(16 citation statements)

References 23 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TM4SF1 is reported to be a prognostic marker in a number of malignant tumors. In lung (14) and colorectal cancer (34) patients, increased expression of TM4SF1 was shown to be significantly associated with early postoperative relapse and shorter survival. In contrast, our study revealed that decreased expression of TM4SF1 was significantly associated with shorter survival and early local spread in PDAC patients, suggesting that TM4SF1 plays an inhibitory role in pancreatic cancer relapse and tumor progression.…”

Section: Discussionmentioning

confidence: 99%

TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells

Zheng

Ohuchida

Chen

et al. 2015

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. The cell surface protein Transmembrane 4 L6 family member 1 (TM4SF1) has been detected in various tumors, and its expression on tumor cells is implicated in cancer cell metastasis and patient prognosis. The role of TM4SF1 in malignant tumors remains poorly understood, particularly in pancreatic cancer. We performed immunohistochemical staining to analyze the expression of TM4SF1 in resected pancreatic tissues and investigated the correlation between TM4SF1 expression and prognosis. The function of TM4SF1 in the invasion and migration of pancreatic cancer cells was analyzed in vitro using an RNA interference technique. In pancreatic cancer tissues, TM4SF1 expression was detected in cancer cells, and patients with high tumor levels of TM4SF1 showed longer survival times than those with low TM4SF1 levels (P=0.0332). In vitro, reduced TM4SF1 expression enhanced the migration (P<0.05) and invasion (P<0.05) of pancreatic cancer cells partially via decreased E-cadherin expression. TM4SF1 protein levels were also reduced after TGF-β1-induced epithelial-mesenchymal transition (EMT). TM4SF1 expression is associated with better prognosis in pancreatic cancer. Loss of TM4SF1 contributes to the invasion and migration of pancreatic cancer cells.

show abstract

Section: Discussionmentioning

confidence: 99%

TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells

Zheng

Ohuchida

Chen

et al. 2015

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…In a more recent study, the sensitivity and specificity of SEPT-9 were confirmed with 73% and 91%, respectively (12). Guanylyl cyclase C (GCC) RNA (5) and L6 RNA (6) showed high sensitivity with 74% and 79% at 95% and 100% specificity but have not yet been extensively validated.…”

mentioning

confidence: 98%

“…Carcinoembryonic antigen (CEA) and carbohydrate antigens, for example, CA19-9 have been assessed more intensely but with varying results depending on the study design and the study population (4). Recently, nucleic acid-based markers, including RNA, DNA, and epigenetic modifications, have come into focus (5)(6)(7)(8)(9)(10)(11)(12). Although some of the markers, for example, a panel of 5 RNA markers (7) or hypomethylated SEPT-9 DNA (11), showed good sensitivities of 88% and 68%, the respective specificities of 69% and 89% will burden a high number of patients with a false-positive result if used for screening.…”

mentioning

confidence: 99%

A Combination of Serum Markers for the Early Detection of Colorectal Cancer

Wild

Andres

Rollinger

et al. 2010

Clinical Cancer Research

121

110

View full text Add to dashboard Cite

Purpose: Fecal occult blood testing is recommended as first-line screening to detect colorectal cancer (CRC). We evaluated markers and marker combinations in serum as an alternative to improve the detection of CRC.Experimental Design: Using penalized logistic regression, 6 markers were selected for evaluation in 1,027 samples (301 CRC patients, 143 patients with adenoma, 266 controls, 141 disease controls, and 176 patients with other cancer). The diagnostic performance of each marker and of marker combinations was assessed.Results: To detect CRC from serum samples, we tested 22 biomarkers. Six markers were selected for a marker combination, including the known tumor markers CEA (carcinoembryonic antigen) and CYFRA 21-1 as well as novel markers or markers that are less routinely used for the detection of CRC: ferritin, osteopontin (OPN), anti-p53, and seprase. CEA showed the best sensitivity at 95% specificity with 43.9%, followed by seprase (42.4%), CYFRA 21-1 (35.5%), OPN (30.2%), ferritin (23.9%), and anti-p53 (20.0%). A combination of these markers gave 69.6% sensitivity at 95% specificity and 58.7% at 98% specificity. Focusing on International Union against Cancer (UICC) stages 0-III reduced the sensitivity slightly to 68.0% and 53.3%, respectively. In a subcollective, with matched stool samples (75 CRC cases and 234 controls), the sensitivity of the marker combination was comparable with fecal immunochemical testing (FIT) with 82.4% and 68.9% versus 81.8% and 72.7% at 95% and 98% specificity, respectively.Conclusions: The performance of the serum marker combination is comparable with FIT. This provides a novel tool for CRC screening to trigger a follow-up colonoscopy for a final diagnosis. Clin Cancer Res; 16(24); 6111-21. Ó2010 AACR.The early detection of colorectal cancer (CRC) significantly improves the prognosis of patients and is a key factor to reduce the mortality from CRC (1). Recently, the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology have issued joint guidelines for CRC screening to include well-known procedures as guaiac-based fecal occult blood testing (FOBT) and fecal immunochemical testing (FIT), colonoscopy, sigmoidoscopy, and double-contrast barium enema, but also 2 more recent methods, computer tomography colonography and fecal DNA testing (2). The guidelines of the U.S. Preventive Services Task Force have also been updated but do not include the latter 2 methods (3).Serum-based, minimally invasive markers would be highly attractive for CRC screening as they could easily be integrated in any health checkup without the need of additional stool sampling. Although numerous biomarkers are under evaluation for the detection of CRC from serum, none of them has sufficient sensitivity and specificity to be considered in the current guidelines (4). Carcinoembryonic antigen (CEA) and carbohydrate antigens, for example, CA19-9 have been assessed more intensely but with varying results depending on the study design and the s...

show abstract

“…These Francisco, CA)]. TM4SF1 is also being evaluated as a diagnostic marker for colorectal and gastric cancers and as a target for therapy with monoclonal antibodies (90,91).…”

Section: And the References Therein)mentioning

confidence: 99%

Expression profiling reveals novel pathways in the transformation of Melanocytes to Melanomas.

Hoek¹,

Rimm²,

Williams³

et al. 2004

Pigment Cell Res

361

107

View full text Add to dashboard Cite

show abstract

Diagnosis and Monitoring of Colorectal Cancer by L6 Blood Serum Polymerase Chain Reaction Is Superior to Carcinoembryonic Antigen-Enzyme-Linked Immunosorbent Assay

Abstract: L6 is more sensitive and precise than carcinoembryonic antigen in diagnosing and monitoring colorectal cancer.

Cited by 26 publications

References 23 publications

TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells

TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells

A Combination of Serum Markers for the Early Detection of Colorectal Cancer

Expression profiling reveals novel pathways in the transformation of Melanocytes to Melanomas.

Contact Info

Product

Resources

About